Hunterian Medicine — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Hunterian Medicine is a private, preclinical-stage biotechnology company founded in 2018 and based in San Diego. The company has developed a proprietary '2-for-1' bidirectional promoter technology that shrinks the genetic instructions for CRISPR, allowing it to be packaged within the limited capacity of a single AAV vector for efficient in vivo delivery. This platform is designed to unlock the therapeutic potential of CRISPR for a broad range of genetic disorders. The company is led by its founder and CEO, Dr. Vinod Jaskula-Ranga, a recognized CRISPR expert, and is focused on advancing its technology toward the clinic through internal development and potential partnerships.

Genetic Diseases

Technology Platform

Patented '2-for-1' bidirectional promoter enabling efficient packaging and delivery of CRISPR systems via a single AAV vector.

Opportunities

The platform addresses the major bottleneck in CRISPR therapeutics, potentially enabling cures for thousands of genetic diseases with high unmet need.

Success could position Hunterian as a key enabler for the entire field, creating value through both internal pipeline development and high-value licensing deals.

Risk Factors

The technology is unproven in humans and faces significant preclinical validation hurdles.

The company operates in an intensely competitive and capital-intensive space, with reliance on future fundraising in an uncertain financial climate.

Competitive Landscape

Hunterian competes with numerous biotechs and large pharma (e.g., CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Beam Therapeutics) all working on CRISPR delivery. Its differentiation is a specific solution to the AAV packaging problem, competing against alternative delivery methods like lipid nanoparticles and the development of smaller Cas enzymes.

More companies in CRISPR / Gene Editing →More companies in United States →